{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluarix&page=17",
    "query": {
      "intervention": "Fluarix",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1159,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluarix&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluarix&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T22:32:53.629Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04667117",
      "title": "A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Quadrivalent influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "iDMT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2021-01-14",
      "completion_date": "2023-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04667117"
    },
    {
      "nct_id": "NCT06863142",
      "title": "Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Prevention",
        "Seasonal Influenza"
      ],
      "interventions": [
        {
          "name": "VRC-FLUMOS0116-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALFQ",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2025-04-28",
      "completion_date": "2027-02-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06863142"
    },
    {
      "nct_id": "NCT01985997",
      "title": "Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Observation Safety"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 95000,
      "start_date": "2014-01",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2016-09-07",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01985997"
    },
    {
      "nct_id": "NCT03035396",
      "title": "Clinical Performance of the Diassess Influenza A and B Test",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Influenza, Human",
        "Influenza",
        "Flu"
      ],
      "interventions": [
        {
          "name": "Diassess Influenza A and B Test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Diassess Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 567,
      "start_date": "2016-12-29",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03035396"
    },
    {
      "nct_id": "NCT00380679",
      "title": "Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Risk for Serious Influenza",
        "High Risk for Pneumonia"
      ],
      "interventions": [
        {
          "name": "Influenza vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal polysaccharide vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Louisiana State University Health Sciences Center in New Orleans",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2005-12",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2006-09-26",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 2,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00380679"
    },
    {
      "nct_id": "NCT03339713",
      "title": "A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.RSV.preF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2017-12-07",
      "completion_date": "2018-07-23",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 1,
      "location_summary": "Mt. Pleasant, South Carolina",
      "locations": [
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03339713"
    },
    {
      "nct_id": "NCT00138281",
      "title": "Influenza Immunity Against Pandemic Respiratory Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FluMist",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138281"
    },
    {
      "nct_id": "NCT03999554",
      "title": "Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A"
      ],
      "interventions": [
        {
          "name": "LD Sing2016 M2SR H3N2 influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MD Sing2016 M2SR H3N2 influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HD Sing2016 M2SR H3N2 influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LD Bris10 M2SR H3N2 influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "FluGen Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 206,
      "start_date": "2019-09-03",
      "completion_date": "2020-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Lenexa, Kansas • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999554"
    },
    {
      "nct_id": "NCT02768805",
      "title": "Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Virus Diseases",
        "RNA Virus Infections",
        "Respiratory Tract Diseases",
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "15 µg/strain of Quadrivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 µg/strain of Quadrivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg/strain of the licensed quadrivalent vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medicago",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 900,
      "start_date": "2016-03-02",
      "completion_date": "2016-11-26",
      "has_results": false,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • South Miami, Florida • Endwell, New York",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Endwell",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02768805"
    },
    {
      "nct_id": "NCT04963166",
      "title": "Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza Immunity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 65,
      "start_date": "2021-09-24",
      "completion_date": "2023-12-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-19T22:32:53.629Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04963166"
    }
  ]
}